IJCS | Volume 33, Nº1, January / February 2019

78 15. Magalhães LP, Figueiredo MJO, Cintra FD, Saad EB, Kuniyoshi RR, Teixeira RA, et al. II Diretrizes Brasileiras de Fibrilação Atrial. Arq Bras Cardiol. 2016;106(4):1-22. 16. Steffel J, Verhamme P, Potpara T, Albaladejo P, Antz M, Desteghe et al. ESC Scientific Document Group; The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal.2018; 39(16):1330–1393. 17. Almeida ED, Guimarães RB, Stephan LS, MedeirosAK, Foltz K, Santanna RT, et al. Clinical Differences between Subtypes of Atrial Fibrillation and Flutter: Cross-Sectional Registry of 407 Patients. Arq Bras Cardiol. 2015;105(1) 3–10. 18. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. The Changing Landscape for Stroke? Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69(7):777–85. 19. Ten Cate V, ten Cate H, Verheugt FWA. The global anticoagulant registry in the FIELD-atrial fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands. Netherlands Hear J. 2016;24(10):574–80. 20. Nishimura RA, OttoCM, BonowRO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2017; 70(2):252-289. 21. Hsu JC, Maddox TM, Kennedy KF, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, Marcus GM. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke RiskInsights From the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1(1):55–62. 22. Apenteng PN, Gao H, Hobbs FR, Fitzmaurice DA, UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry. BMJ Open 2018;8(1):e 018905. 23. Luger S, Hohmann C, Kraft P, Halmer R, Gunreben I, Neumann-Haefelin T, et al. Prescription Frequency and Predictors for the Use of Novel Direct Oral Anticoagulants for Secondary Stroke Prevention in the First Year after Their Marketing in Europe –AMulticentric Evaluation. Int J Stroke. 2014;9(5):569–75. 24. Eikelboom JW, Connolly SJ, BrueckmannM, Granger CB, KappeteinAP, Mack MJ, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med. 2013;369(13):1206–14. 25. Rao MP, Ciobanu AO, Lopes RD, Fox KA, Xian Y, Pokorney SD, et al. A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): Design and rationale. Am Heart J. 2016 Jun;176:107–13. Geraldes et al. Oral anticoagulation in AF Int J Cardiovasc Sci. 2020;33(1):68-78 Original Article This is an open-access article distributed under the terms of the Creative Commons Attribution License